Table 1  Baseline characteristics of study population grouped by number of MetS components (after 2:1 PS matching)

Age, mean ± SD

61.73 ± 11.68

61.65 ± 11.00

-0.03

Male sex

39,474 (50.43%)

20,507 (49.33%)

-0.02

Index year

0.01

  2002–2003

16,592 (21.2%)

8647 (20.8%)

  2004–2005

20,120 (25.7%)

10,634 (25.58%)

  2006–2007

20,990 (26.82%)

11,328 (27.25%)

  2008–2009

20,572 (26.28%)

10,960 (26.37%)

Smoking

413 (0.53%)

264 (0.64%)

0.01

Alcohol drinking

410 (0.52%)

279 (0.67%)

0.02

Comorbidity

  Liver disease

18,538 (23.68%)

10,401 (25.02%)

0.01

  CHD

26,946 (34.43%)

14,053 (33.81%)

-0.05

  H. pylori infection

119 (0.15%)

82 (0.20%)

0.01

  CKD

2572 (3.29%)

1530 (3.68%)

0.01

  Renal transplantation

9 (0.01%)

6 (0.01%)

0.001

Number of prescribed medications

  Aspirin

0.01

    0–1

55,047 (70.33%)

28,235 (67.92%)

    2–5

8556 (10.93%)

4593 (11.05%)

    6–10

6353 (8.12%)

3557 (8.56%)

    ≥11

8318 (10.63%)

5184 (12.47%)

  Non-aspirin NSAID

0.05

    0–1

28,882 (36.90%)

14,126 (33.98%)

    2–5

17,541 (22.41%)

9531 (22.93%)

    6–10

11,679 (14.92%)

6547 (15.75%)

    ≥11

20,172 (25.77%)

11,365 (27.34%)

  Statins

0.05

    0–1

55,090 (70.38%)

27,520 (66.2%)

    2–5

13,758 (17.58%)

7181 (17.27%)

    6–10

6902 (8.82%)

4541 (10.92%)

    ≥11

2524 (3.22%)

2327 (5.6%)

  Sex hormones/endocrine therapy

0.03

    0–1

74,406 (95.06%)

39,246 (94.41%)

    2–5

1903 (2.43%)

1177 (2.83%)

    6–10

897 (1.15%)

525 (1.26%)

    ≥11

1068 (1.36%)

621 (1.49%)

Data are presented as mean ± SD or n (%).

Abbreviations: CHD, coronary heart disease; CKD, chronic kidney disease; NSAID, nonsteroidal anti-inflammatory drugs; Std Diff, standardized difference.